Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
Doxorubicin hydrochloride (HB4183)
Description:Antibiotic. DNA topisomerase II inhibitor. Apoptosis inducer.
Purity:>99%
Doxycycline hyclate (HB4608)
Description:Broad-spectrum antibiotic. Used in inducible Tet-on/ Tet-off gene expression systems for gene editing.
Purity:>95%
Epirubicin hydrochloride (HB4187)
Description:DNA synthesis and function inhibitor. Inhbits DNA topoisomerase II
Purity:>98%
G418 disulfate salt (HB3906)
Description:Antibiotic. Widely used in cell culture. Protein synthesis inhibitor.
Gatifloxacin (HB3263)
Description:Antibiotic; bacterial type II topoisomerase inhibitor. Activates ESC short term renewal.
Purity:>98%
Geldanamycin (HB3311)
Description:Selective Hsp90 inhibitor. Breast cancer stem cell inhibitor.
Purity:>98%